FDA approves first generic versions of Zyprexa

(AP) -- Federal health officials on Monday approved the first generic versions of the blockbuster drug Zyprexa, an expensive treatment for schizophrenia and bipolar mood disorder.

Zyprexa posted sales of $5.7 billion last year for drugmaker Eli Lilly & Co Inc., according to prescription tracking company IMS Health.

The new low-cost versions of the drug will be marketed by Indian generic drugmaker Dr. Reddy's Laboratories and by Teva Pharmaceutical Industries, based in Israel.

Zyprexa is part of a class of medications called atypical antipsychotics that effect levels of dopamine, a brain chemical that controls behavior, mood and movement. Doctors overwhelmingly embraced the drugs in the 1990s over older treatments, because they were thought to be less likely to cause side effects like muscle tremors and spasms. The newer medications have their own side effects; including weight gain, high blood sugar and drowsiness.

Drugs like Zyprexa can cost up to $500 per month. Generic versions can cut the cost by up to 80 percent.

FDA approves of medications after the patent on the original drug expires or has been ruled invalid in court.

Shares of Indianapolis-based Eli Lilly rose 12 cents to $38.19 in afternoon trading.

3 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

Mississippi sues pharmaceutical company

Jul 25, 2006

Mississippi has filed a legal action against Eli Lilly and Co. alleging a plan to defraud the state of millions of dollars in Medicaid reimbursements.

FDA panel backs 3 psychiatric drugs for kids

Jun 11, 2009

(AP) -- Advisers to the Food and Drug Administration said Wednesday that three blockbuster psychiatric drugs appear safe and effective for children and adolescents, despite side effects that can increase the risk of diabetes.

Lilly, Boehringer collaborate on diabetes drugs

Jan 11, 2011

(AP) -- Eli Lilly will pay Boehringer Ingelheim $387.4 million and collaborate with the German drugmaker to develop diabetes drugs with the U.S. pharmaceutical company facing the expiration of some of its key patents.

FDA weighs approval of psychiatric drugs for kids

Jun 05, 2009

(AP) -- Three blockbuster psychiatric drugs currently approved for adults also appear to work in adolescents, though federal health officials have concerns about exposing younger patients to the drugs' side effects.

Recommended for you

WHO: Millions of Ebola vaccine doses ready in 2015

Oct 24, 2014

The World Health Organization says millions of doses of two experimental Ebola vaccines could be ready for use in 2015 and five more experimental vaccines will start being tested in March.

Added benefit of vedolizumab is not proven

Oct 23, 2014

Vedolizumab (trade name Entyvio) has been approved since May 2014 for patients with moderately to severely active Crohn disease or ulcerative colitis. In an early benefit assessment pursuant to the Act on the Reform of the ...

Seaweed menace may yield new medicines

Oct 22, 2014

An invasive seaweed clogging up British coasts could be a blessing in disguise. University of Greenwich scientists have won a cash award to turn it into valuable compounds which can lead to new, life-saving drugs.

User comments